InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,660.00
(
0.33%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
84.07
(
0.14%
)
Bitcoin
62,826.35
(
-0.35%
)
Post# of 251777
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119605
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 226892

Thursday, 06/25/2020 11:04:45 AM

Thursday, June 25, 2020 11:04:45 AM

Post# of 251777
ASMB starts phase-2 for second-generation HBV CpAM, ABT-H2158:

https://www.globenewswire.com/news-release/2020/06/25/2053349/0/en/Assembly-Biosciences-Initiates-Phase-2-Trial-Evaluating-Second-Generation-Core-Inhibitor-ABI-H2158-for-Chronic-Hepatitis-B-Infection.html

ASMB’s first-generation CpAM, ABI-H0731, has shown only modest efficacy (#msg-152253534).

ENTA’s EDP-514, in phase-2, is also a CpAM.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up